Broke Out Inc (OTCMKTS:BRKO) is causing quite a stir on the OTCBB board. Thanks to an apparent short squeeze and some solid investors awareness advertising campaigns that had led to stock prices of Broke Out Inc (OTCMKTS:BRKO) surge from $3.40 to more than $11 in less than 2 trading sessions. While the company’s fundamentals don’t really justify the current market cap, the short squeeze seems to have triggered trader’s interest looking to make some quick bucks. It would be interesting to see if BRKO perishes or leads to another strong rally today.
Speaking of fundamentals, one micro-cap company that caught our attention today is OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP). OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) is a clinical stage bio pharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology for prostate cancer. The company announced today that it has received a Notice of Allowance for a patent on ProscaVax™, OncBioMune’s cancer vaccine in a Phase 1 trial for relapsed prostate cancer patients, from the European Patent Office. Read more HERE
OBMP has only gone public about six months ago, but the company has been around for more than a decade, founded by the two doctors responsible for the first patented autologous breast cancer vaccine. The company’s portfolio contains patented targeted therapies, including a biosimilar to nab-paclitaxel (Abraxane – Celgene CELG), a paclitaxel conjugate (PGT-OBM) for renal cancer and a vaccine technology, to date formulated for prostate cancer (ProscaVax) and ovarian cancer (OvcaVax). As per a recent seeking alpha article released on OBMP, it looks like OBMP is highly undervalued at the current pps and holds great potential for a much higher appreciation as more data pours in.
Here is an excerpt from the seeking alpha article at: http://seekingalpha.com/article/3943756-small-price-big-upside-new-cancer-treatments-rexahn-oncbiomune
All in all, if a company like Broke Out Inc (OTCMKTS:BRKO) with no solid background and revenues can trade at $11 a share, there remains no doubt that as time progresses OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) could be the talk of WallStreet. Disclaimer